Secondary hyperparathyroidism disease stabilization following calcimimetic therapy

NDT Plus

Volumn 1, Issue SUPPL.1, 2008, Pages

  Frazão, João ^a   Rodriguez, Mariano ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b Hospital Universitario Reina Sofía Avda   (Spain)

Author keywords

Calcimimetic; Calcium sensing receptor; Cinacalcet; Secondary hyperparathyroidism

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; R 568; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

CALCIUM INTAKE; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; DATA ANALYSIS; DIET SUPPLEMENTATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG POTENTIATION; DRUG USE; HUMAN; LONG TERM CARE; NONHUMAN; PARATHYROID CELL; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR SENSITIVITY; SECONDARY HYPERPARATHYROIDISM;

EID: 39449129617     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfm039     Document Type: Conference Paper

References (28)

1. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 1998; 53: 1083-1088
2. Mizobuchi M, Hatamura I, Ogata H et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004; 15: 2579-2587
3. 2+ -sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 1598-1606
4. Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63: 248-254
5. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Neprol 2005; 16: 800-807
6. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-583
7. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
8. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: A key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288: F253-F7264
9. Rodriguez M, Canalejo A, Garfia B et al. Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int Suppl 2002; 155-160
10. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
11. Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia, in a rat model of secondary hyperparathyroidism. Kidney Int 2005; 67: 467-1476
12. Kawata T, Imanishi Y, Kobayashi K et al. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab 2006; 24: 300-306
13. Garfia B, Canadillas S, Canalejo A et al. Regulation of parathyroid vitamin D receptor expression by extracellular calcium. J Am Soc Nephrol 2003; 13: 2945-2952
14. Silver J, Naveh-Many T, Mayer H et al. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986; 78: 1296-1301
15. Rodriguez ME, Almaden Y, Canadillas S et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 2007; 292: F1390-F1395
16. Naveh-Many T, Rahamimov R et al. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995; 96: 1786-1793
17. Wada M, Furuya Y, Sakiyama J et al. The calcimimetic compound NPS R-568 suppresses pkrathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997; 100: 2977-2983
18. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
19. 4 product, and parathyroid hoinione with cardiar, mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
20. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237
21. Block GA, Hulbert-Shearon T, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31: 607-617
22. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatnient goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771
23. Frazão J, Nicolini M, Torregrosa V et al. Cinacalcet HCl effectively reduces intact parathyroid hormone (iPTH) and Ca x P irrespective of the severity of secondary hyperparathyroidism (HPT) [abstract and presentation MO 18]. Presented at: ERA-EDTA Congress, 15-18 May 2004, Lisbon, Portugal
24. Frazão J, Messa P, Cunningham J et al. Early use of cinacalcet (MIMPARA/SENSIPAR) in dialysis patients enables greatest achievement of NKF-KDOQI treatment targets for bone metabolism [abstract SO016]. Presented at: ERA-EDTA Congress, 15-18 July 2006, Glasgow, UK
25. Frazão J, Holzer H, Stummvoll H etal. Cinacalcet (Mimpara/ Sensipar) maintains achievement of NKF-K/DOQI treatment targets for secondary hypaparathyroidism (HPT) i patients on dialysis [abstract SP209]. Presented at: ERA-EDTA Congress, 4-7 June 2005, Istanbul, Turkey
26. Moe SM, Cunningham J, Bommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005; 20: 2186-2193
27. Sprague SM, Nicolini M, Evenepoel P et al. Simultaneous control of PTH and Ca x P is sustained over 2 years of treatruent with Sensipar (cinacalcet HCL) Presented at: Renal. Week, 8-13 November 2005, Philadelphia, PA
28. Cunningham, J, Urena P, Reichel H et al. Long-term efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end stage renal disease (ESRD) [abstract SP210]. Presented at: ERA-EDTA Congress, 4-7 June 2005, Istanbul, Turkey